TCF7 Antibodies

Structure of TCF7

The TCF7 (T-cell factor 7) gene encodes a variable-length transcription factor protein, and the molecular weight of its main subtype is approximately 50-60 kDa. The molecular weight varies among different species, mainly due to the differences in amino acid sequence length and post-translational modifications.

The core structure of the TCF7 protein includes an amino-terminal domain responsible for binding to β -catenin, as well as a highly conserved HBG-box DNA binding domain. This HMG-box domain can specifically recognize and bind to specific sequences on the DNA double helix (such as 5 '-CCTTTGATC-3'), causing significant DNA bending, thereby altering the local chromatin structure and recruiting other transcriptional regulatory factors. Its tertiary structure is stabilized through hydrophobic interactions and hydrogen bond networks, forming a conformation suitable for interaction with DNA and co-activators/co-inhibitors.

Fig. 1 Schematic representation of the resulting TCF1-PU.1 (TCF7-SPI1) fusion protein.¹

Key structural properties of TCF7:

• Highly conserved HMG-box DNA binding domain
• Modular protein structure
• Key amino acid residues regulate DNA binding and signal integration

Functions of TCF7

The transcription factor encoded by the TCF7 gene has the core function of acting as a downstream effector of the Wnt/β-catenin signaling pathway, regulating the transcriptional expression of target genes. This function is mainly reflected in the determination of cell fate and the maintenance of homeostasis.

The activity of TCF7 is not constant but is precisely regulated. Its own expression is induced by multiple signals, and its protein activity can be regulated by various post-translational modifications (such as phosphorylation and acetylation), and depends on competitive binding to β-catenin or inhibitors, thereby forming a dynamic, environment-dependent transcriptional regulatory switch in cells.

Applications of TCF7 and TCF7 Antibody in Literature

• Duan, Yang, et al. "TCF7/SNAI2/miR-4306 feedback loop promotes hypertrophy of ligamentum flavum." Journal of Translational Medicine 20.1 (2022): 468. https://doi.org/10.1186/s12967-022-03677-0 

This study first discovered that TCF7 is highly expressed in ligamentum flavum hypertrophy and confirmed that it can promote cell proliferation and fibrosis. Mechanistically, TCF7 exerts its effect by activating the SNAI2/miR-4306 feedback loop, suggesting that this pathway can serve as a potential therapeutic target.

• Ghosh, Rituparna, and Matthew J. Yousefzadeh. "TCF7‐Linked Immune Resilience: A Salutogenic Biological Warranty for Longevity." Aging Cell 24.6 (2025): e70090. https://doi.org/10.1111/acel.70090 

Research has found that high expression of TCF7 is key to maintaining immune resilience, as it can enhance immune capacity and suppress chronic inflammation. This feature has a weak correlation with age and is a new target for promoting healthy aging.

• Rong, Haixu, et al. "Correlation between TCF7+ T cells and prognosis of patients with oral squamous cell carcinoma." Frontiers in Oncology 12 (2022): 782058. https://doi.org/10.3389/fonc.2022.782058

This study confirmed that TCF7-positive T cells are an independent predictor of postoperative survival in patients with oral squamous cell carcinoma. Incorporating it into existing predictive models (such as TNM staging) can significantly enhance the predictive accuracy and clinical application value of the models.

• Ma, Zhongnan, et al. "TCF7 is highly expressed in immune cells on the atherosclerotic plaques, and regulating inflammatory signaling via NFκB/AKT/STAT1 signaling." Bioscience Reports 42.7 (2022): BSR20212064. https://doi.org/10.1042/BSR20212064 

This study confirmed that single-cell sequencing revealed that genes such as TCF7 are involved in the continuous activation of T cells and macrophages in atherosclerotic plaques through the AKT/NFκB signaling pathway, and are potential therapeutic targets.

• Van Thillo, Quentin, et al. "Oncogenic cooperation between TCF7-SPI1 and NRAS (G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia." Nature Communications 12.1 (2021): 4164. https://doi.org/10.1038/s41467-021-24442-9

This study found that the TCF7-SPI1 fusion gene needs to co-induce T-cell leukemia with NRAS mutations, and its carcinogenesis depends on the interaction of TCF/β-catenin. Blocking this effect can induce the differentiation of cancer cells, providing a new strategy for targeted therapy.

Creative Biolabs: TCF7 Antibodies for Research

Creative Biolabs specializes in the production of high-quality TCF7 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom TCF7 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our TCF7 antibodies, custom preparations, or technical support, contact us at email.